A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
NCT ID: NCT04294810
Last Updated: 2026-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
620 participants
INTERVENTIONAL
2020-03-04
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT03563716
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04665856
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04984811
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
NCT04426825
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
NCT06713798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tiragolumab + Atezolizumab
Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Atezolizumab
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Tiragolumab
Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Placebo + Atezolizumab
Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Atezolizumab
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Matching Placebo
Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
Tiragolumab
Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Matching Placebo
Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
* No prior systemic treatment for metastatic NSCLC
* High tumor tissue PD-L1 expression
* Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
* Adequate hematologic and end-organ function
* For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.
Exclusion Criteria
* Symptomatic, untreated, or actively progressing central nervous system metastases
* Active or history of autoimmune disease or immune deficiency
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
* Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
* Severe infection within 4 weeks prior to initiation of study treatment
* Positive test result for human immunodeficiency virus (HIV)
* Active hepatitis B or hepatitis C
* Treatment with investigational therapy within 28 days prior to initiation of study treatment
* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trial
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rocky Mountain Cancer Center - Denver
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
SCRI Florida Cancer Specialists North
St. Petersburg, Florida, United States
SCRI Florida Cancer Specialists PAN
Tallahassee, Florida, United States
US oncology research at Minnesota Oncology
Saint Paul, Minnesota, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Virginia Cancer Specialists (Fairfax) - USOR
Fairfax, Virginia, United States
Onc & Hem Assoc SW Virginia
Salem, Virginia, United States
Northwest Cancer Specialists - Vancouver
Vancouver, Washington, United States
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Austin Hospital Olivia Newton John Cancer Centre
Heidelberg, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Ordensklinikum Linz Elisabethinen
Linz, , Austria
Klinik Penzing
Vienna, , Austria
Krankenhaus Nord - Klinik Floridsdorf
Vienna, , Austria
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Beijing Cancer Hospital
Beijing, , China
The First Hospital of Jilin University
Changchun, , China
West China Hospital, Sichuan University
Chengdu, , China
Chongqing Cancer Hospital
Chongqing, , China
Fujian Cancer Hospital
Fuzhou, , China
Hainan General Hospital
Haikou, , China
Sir Run Run Shaw Hospital Zhejiang University
Hangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Jinan Central Hospital
Jinan, , China
Meizhou People's Hospital
Meizhou, , China
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, , China
Nantong Tumor Hospital
Nantong, , China
Zhongshan Hospital Fudan University
Shanghai, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Shanghai Pulmonary Hospital
Shanghai, , China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, , China
The First Affiliated Hospital of Xiamen University
Xiamen, , China
Zhejiang Cancer Hospital
Zhejiang, , China
Krankenhaus Nordwest
Frankfurt, , Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, , Germany
Krankenhaus Martha-Maria Halle-Doelau gGmbH
Halle, , Germany
SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
Löwenstein, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, , Germany
Klinik Schillerhöhe
Stuttgart, , Germany
Sotiria Hospital
Athens, , Greece
Metropolitan Hospital
Athens, , Greece
University Hospital of Larissa
Larissa, , Greece
Orszagos Koranyi TBC es Pulmonologiai Intezet
Budapest, , Hungary
Matrai Gyogyintezet
Mátraháza, , Hungary
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház
Szolnok, , Hungary
Azienda Ospedaliera San Giuseppe Moscati
Avellino, Campania, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Napoli, Campania, Italy
Azienda Ospedaliera San Camillo Forlanini
Rome, Lazio, Italy
Policlinico Universitario "Agostino Gemelli"
Rome, Lazio, Italy
Irccs Istituto Europeo di Oncologia (IEO)
Milan, Lombardy, Italy
Asst Di Monza
Monza, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Orbassano, Piedmont, Italy
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
Perugia, Umbria, Italy
IOV - Istituto Oncologico Veneto - IRCCS
Padua, Veneto, Italy
Aichi Cancer Center
Aichi, , Japan
National Cancer Center Hospital East
Chiba, , Japan
Kyushu University Hospital
Fukuoka, , Japan
Sendai Kousei Hospital
Miyagi, , Japan
Niigata Cancer Center Hospital
Niigata, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Kindai University Hospital
Osaka, , Japan
Saitama Cancer Center
Saitama, , Japan
NHO Kinki-Chuo Chest Medical Center
Sakaishi, , Japan
Shizuoka Cancer Center
Shizuoka, , Japan
National Cancer Center Hospital
Tokyo, , Japan
The Cancer Institute Hospital of JFCR
Tokyo, , Japan
Health Pharma Professional Research
CD Mexico, Mexico CITY (federal District), Mexico
Cryptex Investigacion Clinica SA de CV
México, Mexico CITY (federal District), Mexico
AVIX Investigación Clínica S.C
Monterrey, Nuevo León, Mexico
Cuidados oncologicos
Querétaro City, Querétaro, Mexico
Ziekenhuis Gelderse Vallei
Ede, , Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, , Netherlands
Hagaziekenhuis, locatie Leyweg
The Hague, , Netherlands
Instituto Regional de Enfermedades Neoplásicas del Sur
Arequipa, , Peru
Instituto Nacional de Enfermedades Neoplasicas
Lima, , Peru
Clinica Internacional, Sede San Borja
Lima, , Peru
Clinica Ricardo Palma
San Isidro, , Peru
Uniwersyteckie Centrum Kliniczne
Gda?sk, , Poland
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
Olsztyn, , Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
Poznan, , Poland
Main Military Clinical Hospital named after N.N. Burdenko
Moscow, Moscow Oblast, Russia
MEDSI Clinical Hospital on Pyatnitsky Highway
Moscow, Moscow Oblast, Russia
Institute of Oncology
Saint Petersburg, Sankt-Peterburg, Russia
St. Petersburg Med Univ
Saint Petersburg, Sankt-Peterburg, Russia
St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
Saint Petersburg, Sankt-Peterburg, Russia
Clinical Center of Serbia
Belgrade, , Serbia
University Hospital Medical Center Bezanijska kosa
Belgrade, , Serbia
Chungbuk National University Hospital
Cheongju-si, , South Korea
Seoul National University Bundang Hospital
Gyeonggi-do, , South Korea
Ajou University Medical Center
Gyeonggi-do, , South Korea
Gachon University Gil Medical Center
Incheon, , South Korea
Chonnam National University Hwasun Hospital
Jeollanam-do, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Kangbuk Samsung Medical Center
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
St. Vincent's Hospital
Suwon, , South Korea
Hospital Universitario Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital General Universitario de Alicante
Alicante, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Hospital Universitario Puerta de Hierro - Majadahonda
Madrid, , Spain
Hospital Universitario Virgen del Rocío
Madrid, , Spain
Hospital Regional Universitario de Malaga
Málaga, , Spain
Hosp Clinico Univ Lozano Blesa
Zaragoza, , Spain
Inselspital Bern
Bern, , Switzerland
CHUV
Lausanne, , Switzerland
HOCH Health Ostschweiz, Kantonsspital St. Gallen
Sankt Gallen, , Switzerland
Chang Gung Memorial Hospital - Linkou Branch
Guishan Dist., , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Taipei Medical University ?Shuang Ho Hospital
New Taipei City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung Uni Hospital
Tainan, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
National Taiwan University Hospital
Zhongzheng Dist., , Taiwan
Chulalongkorn Hospital
Bangkok, , Thailand
Ramathibodi Hospital
Bangkok, , Thailand
Faculty of Med. Siriraj Hosp.
Bangkok, , Thailand
Songklanagarind Hospital
Songkhla, , Thailand
Adana Baskent University Hospital
Adana, , Turkey (Türkiye)
Hacettepe University Medical Faculty
Ankara, , Turkey (Türkiye)
Istanbul University Cerrahpasa Faculty of Medicine
Istanbul, , Turkey (Türkiye)
Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
Izmir, , Turkey (Türkiye)
Goztepe Prof.Dr. Suleyman Yalcin City Hospital
Kadiköy, , Turkey (Türkiye)
Inonu University Medical Faculty of Medicine
Malatya, , Turkey (Türkiye)
City Clinical Hospital #4
Dnipropetrovsk, , Ukraine
ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
Kryvyi Rih, , Ukraine
Uzhgorod Nat. University Central Municip Hosp
Uzhhorod, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-002925-31
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2022-502482-17-00
Identifier Type: CTIS
Identifier Source: secondary_id
GO41717
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.